2020 was an interesting year for the biotech industry and the BioHealth Capital Region as we adjusted to continue moving forward during the COVID-19 Pandemic. While the biggest stories in terms of dollars were related to the Coronavirus and funding to create a vaccine in record time, that didn’t stop other biotech companies from working hard to develop their research, science, and/or devices.
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.
Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
5 Questions with Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S.
5 Questions with Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S. “5 Questions With……” is a new BioBuzz series where we reach out to interesting people [….]
5 Questions With John Trainer, CFO, NexImmune, Inc. “5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share [….]
NexImmune Bolsters Leadership Team Adding Former MedImmune Executive as Chief Financial Officer GAITHERSBURG, Md., Jan. 09, 2020 (Excerpts below were originally published on GLOBE NEWSWIRE) NexImmune, a clinical-stage biopharmaceutical company [….]
NexImmune Appoints Industry Veteran Chief Medical Officer to Executive Team GAITHERSBURG, Md., Jan. 09, 2020 (originally published on GLOBE NEWSWIRE) NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on [….]
BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]
Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome October 31, 2019 07:30 ET | Source: NexImmune, Inc. IND clearance enables [….]
Serial Entrepreneurs of the Biohealth Capital Region A strong group of entrepreneurs ready and willing to innovate, fund and lead new bioscience companies is essential to the creation and sustainability [….]